From 2015 to 2023, long-term opioid therapy declined in the USA. Approximately 4 million to 5 million patients were prescribed long-term opioid therapy in 2023. Long term opioid use remains a challenge https://t.co/N5s7mYvXSw https://t.co/YHdTbHLB4q

Managing PsA disease activity across GRAPPA domains with a JAKi: how could a domain-based framework inform care for your patients with PsA? Explore efficacy & safety data. Hear expert insights. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Js5fGoJduH https://t.co/FVEictVFRM

Claims data 2,751 #AAV patients - 6.2% developed #PJP infx. w/ predictors: age, max GC dose, rituximab, CTX, & PJP prophylaxis had Good concordance (0.70) @2mos & 0.66@1yrs. W/ monthly risk of 1.0%, prophylaxis yielded 34 potentially preventable PJP cases https://t.co/c2ObDnmfYp https://t.co/Ljr5maHZcr

Single-centre retrosp study of established 257 PMR pts. 98 referred by GPs were for Dx uncertainty (51 vs 14%), less for relapse (27%) or recurrence (11%). PMR Dx accuracy better by Rheums vs PCPs (83% v 62%, P < 0.05) https://t.co/DvTKeuGa4Q https://t.co/wQDXR46k5F

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/cJCnTckoPz https://t.co/VUlb7Lz70N

ILD in RA - Recent Advances. Dr. Jeffrey Sparks ILD in RA – Dr. Jeffrey Sparks In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Jeffrey Sparks reviews the latest advances shaping diagnosis and management of ILD in RA. 🎧 Listen here: https://t.co/U5cZVlgAka #Rheumatology #ILD https://t.co/0AWneSEPjP

CDC: In 2023, age-adjusted prevalence of U.S. adults (>20 yrs) with obesity was 40.3% (9.7% with severe obesity; 31.7% overweight). BMI data from NHANES, & the National Center for Health Statistics https://t.co/kH9ajbUJ2m https://t.co/utbGWf4D12

Couldn’t attend https://t.co/4UQlqwujiR 2026? You can now watch the entire meeting On Demand. This high-impact program features leading experts discussing: • RA outcomes and pathogenesis • Obesity, inflammation, and rheumatic disease • Treatment decisions in Psoriatic https://t.co/mre5aQcR8M

Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis The original CRA/SPARCC recommendations endorsed IL-17i and TNFi as equivalent second-line options for adults with active axSpA who fail an adequate NSAID trial. JAK inhibitors were reserved for patients with prior https://t.co/1GNb3Tc5gR

Korean Insurance claims nested case–control study of 27,410 RA pts - 5482 w/ > comorbid Dsx Vs 21,928 w/ < 10 comorbd Dz. Having >10 signif incr Serious infx (OR 1.44), opportunistic (21.9)& Hzoster (1.18); mainly skin & soft tissue infx - NOT fatal infx. https://t.co/qDrU3BXYzd

What’s New PsA? (4.3.2026) Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials. https://t.co/Ew1wAFDfa1 https://t.co/AJfqqEAdik

Machine learning predicts macrophage activation syndrome in adult Still's disease - 312 AOSD - XGBoost model had 5 predictors: ferritin, splenomegaly, Plt#, cholesterol, & ESR (AUC 0.839, sensit 0.824, specificity 0.710. https://t.co/QrogaCYPCT https://t.co/Z6WgCnFTfx